In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altana's Daxas Breaks from the Pack

Executive Summary

Altana's Phase III PDE-4 inhibitor Daxas has shown promising preliminary results in a second late-stage clinical trial. But class-wide concerns about the long-term safety and efficacy of this new generation of respiratory drugs-and the recent high-profile thrashing of GSK's Ariflo at the hands of an FDA advisory committee-suggest that the devil may be in the details, which aren't due to be released until May 2004. But as the competition falters, and if Daxas can remain standing, the drug could transform Altana into a truly global pharmaceutical firm while providing Pfizer with the best one-two respiratory punch in the industry.

You may also be interested in...



Boehringer's Spiriva: Advancing COPD Therapy

Boehringer Ingelheim's new COPD treatment, Spiriva, could be a blockbuster--particularly if its worldwide marketing partner Pfizer can increase diagnosis of the disease and expand COPD drugs' prescribing base from specialists to GPs. But, complicating matters for Boehringer, Pfizer--through its proposed acquisition of Pharmacia--will also market the PDE-4 inhibitor roflumilast, Altana's next-generation COPD therapy.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel